Role of RANTES in Pneumococcal Immunopathogenesis

RANTES 在肺炎球菌免疫发病机制中的作用

基本信息

  • 批准号:
    7070537
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-08-01 至 2006-10-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Streptococcus pneumoniae infections are becoming increasingly difficult to manage due to the inability of susceptible individuals to mount appropriate anti -polysaccharide and, to a lesser degree, -surface protein antibody responses as well as increasing antibiotic resistance. Hence, new prophylactic interventions and understanding of pneumococcal immunopathogenesis are greatly needed. This proposal stems from and focuses on our recent findings that RANTES (regulated on activation, normal T cell expressed and secreted) significantly, yet differentially, enhances mucosal and systemic immunity. We present preliminary data that RANTES mRNA mucosal expression is elevated during the primary inflammatory/adaptive recognition response to pneumococcal carriage, which suggests that RANTES is essential for protective mucosal immunity to S. pneumoniae infections. RANTES, MIP-1alpha, and CCR5 polymorphisms resulting in diminished expression are also associated with increased susceptibility to- and progression of- other mucosal pathogens in man. In this regard, our preliminary results show that RANTES blockade leads to the transition of pneumococcal carriage to lethal pneumonia in a mouse model of carriage, using S. pneumoniae strain EF3030. These findings provide the rationale to support the hypothesis that RANTES is essential for the induction of protective mucosal and systemic adaptive immunity against S. pneumoniae. We have emphasized in vivo approaches using mouse models of pneumococcal -carriage and -pneumonia to test this hypothesis. Aim One will assess the recognition phase host immune response to EF3030 challenge in normal, RANTES- or T cell- blocked mice. Aim Two will characterize the adaptive (activation/effector phase) mucosal and systemic immune responses to the phosphorylcholine determinant of C-polysaccharide (PC) and pneumococcal surface adhesin A (PsaA) during pneumococcal disease in control Ab-treated or RANTES-inhibited mice. Aim Three will ascertain the role of RANTES in protection against carriage and/or pneumonia induced by wild type, mutant surface protein (e.g., psaA-) and rough EF3030 strains. This study will provide important and new information regarding the cellular and molecular mechanisms that RANTES uses to induce protective immunity against pneumococci.
描述(由申请人提供):肺炎链球菌感染变得越来越难以控制,因为易感个体无法产生适当的抗多糖,在较小程度上,表面蛋白抗体反应以及抗生素耐药性的增加。因此,迫切需要新的预防干预措施和对肺炎球菌免疫发病机制的了解。这一建议源于并关注于我们最近的研究结果,即RANTES(调节激活,正常T细胞的表达和分泌)显著但差异地增强了粘膜和全身免疫。我们提供的初步数据表明,在对肺炎球菌携带的原发性炎症/适应性识别反应中,RANTES mRNA粘膜表达升高,这表明RANTES对肺炎链球菌感染的保护性粘膜免疫至关重要。RANTES、mip -1 α和CCR5多态性导致表达减少也与人类对其他粘膜病原体的易感性增加和进展有关。在这方面,我们的初步结果表明,在使用肺炎链球菌菌株EF3030的小鼠载体模型中,RANTES阻断导致肺炎球菌载体向致死性肺炎转变。这些发现为RANTES对诱导保护性粘膜和系统性肺炎链球菌适应性免疫至关重要的假设提供了理论依据。我们强调了使用肺炎球菌携带和肺炎小鼠模型的体内方法来验证这一假设。目的一将评估正常、RANTES或T细胞阻断小鼠对EF3030攻击的识别期宿主免疫反应。目的二将在对照抗体处理或rantes抑制小鼠中表征肺炎球菌疾病期间对c -多糖(PC)和肺炎球菌表面粘附素A (PsaA)的磷酸化胆碱决定因素的适应性(激活/效应期)粘膜和全身免疫反应。目的三将确定RANTES在防止野生型、突变表面蛋白(如psaA-)和粗糙的EF3030菌株引起的携带和/或肺炎中的作用。这项研究将为RANTES用于诱导对肺炎球菌的保护性免疫的细胞和分子机制提供重要的新信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James W Lillard其他文献

PROSTATE CANCER CELL-SPECIFIC DRUG TARGETING USING NOVEL NANOPARTICLES
  • DOI:
    10.1016/s0022-5347(08)60663-1
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Rajesh Singh;Shailesh Singh;James W Lillard
  • 通讯作者:
    James W Lillard
CCL25 BLOCKADE INHIBITS ANTI-APOPTOTIC SIGNALS IN PROSTATE CANCER CELLS AND ENHANCES THE EFFICACY OF ETOPOSIDE
  • DOI:
    10.1016/s0022-5347(09)61131-9
  • 发表时间:
    2009-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Praveen Kumar Sharma;Rajesh Singh;John W Eaton;James W Lillard;Kristian R Novakovic;William E Grizzle;Leland W k Chung;Shailesh Singh
  • 通讯作者:
    Shailesh Singh
XPCLAD© NANOPARTICLE-MEDIATED PROSTATE TUMOR AND T REGULATORY CELL TARGETING AND APOPTOSIS
  • DOI:
    10.1016/s0022-5347(09)61116-2
  • 发表时间:
    2009-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Rajesh Singh;Shailesh Singh;Praveen Kumar Sharma;James W Lillard
  • 通讯作者:
    James W Lillard

James W Lillard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James W Lillard', 18)}}的其他基金

Detection of HIV proteins in urine to diagnose infection
检测尿液中的 HIV 蛋白以诊断感染
  • 批准号:
    9908301
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Novel pharmacogenomic approach for identifying T cell epitopes in replacement FVI
用于识别替代 FVI 中 T 细胞表位的新药物基因组学方法
  • 批准号:
    8646315
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Treatment of Colitis using a Novel CXCR3 Biologic Antagonist
使用新型 CXCR3 生物拮抗剂治疗结肠炎
  • 批准号:
    8734398
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Evaluation of the Antigenicity of Black Restricted FVIII Haplotypes and Haplotype
Black限制性FVIII单倍型和单倍型的抗原性评价
  • 批准号:
    8591385
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Treatment of Colitis using a Novel CXCR3 Biologic Antagonist
使用新型 CXCR3 生物拮抗剂治疗结肠炎
  • 批准号:
    8591890
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
CELLS AND TISSUES
细胞和组织
  • 批准号:
    8357152
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
CELLS AND TISSUES
细胞和组织
  • 批准号:
    8166164
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
ROLE OF CHEMOKINES IN MUCOSAL IMMUNITY: ORAL, RESPIRATORY & UROGENITAL PATHOGENS
趋化因子在粘膜免疫中的作用:口腔、呼吸道
  • 批准号:
    7335986
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
ROLE OF CHEMOKINES IN MUCOSAL IMMUNITY: ORAL, RESPIRATORY & UROGENITAL PATHOGENS
趋化因子在粘膜免疫中的作用:口腔、呼吸道
  • 批准号:
    7164251
  • 财政年份:
    2005
  • 资助金额:
    --
  • 项目类别:
Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership
莫尔豪斯医学院/塔斯基吉大学/UAB 比较。
  • 批准号:
    8727715
  • 财政年份:
    2005
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

Adhesin蛋白在铜绿假单胞菌中的致病功能及其机制研究
  • 批准号:
    2025JJ81015
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目

相似海外基金

Probing the role of heterogeneity in streptococcal interactions
探讨异质性在链球菌相互作用中的作用
  • 批准号:
    10841244
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Adhesin Amyloid Biology
粘附素淀粉样蛋白生物学
  • 批准号:
    10726038
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Safety and immunogenicity of nasal inoculation with recombinant Neisseria lactamica expressing Factor H binding protein and Neisseria Adhesin A.
表达 H 因子结合蛋白和奈瑟氏球菌粘附素 A 的重组乳酰胺奈瑟氏球菌经鼻接种的安全性和免疫原性。
  • 批准号:
    MR/X019284/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Nanomechanics of Tubulin Extraction from Microtubules and Adhesin Catch-Bond Rupture
从微管中提取微管蛋白的纳米力学和粘附素捕获键断裂
  • 批准号:
    2139572
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Probing the role of heterogeneity in streptococcal interactions
探讨异质性在链球菌相互作用中的作用
  • 批准号:
    10662775
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Probing the role of heterogeneity in streptococcal interactions
探讨异质性在链球菌相互作用中的作用
  • 批准号:
    10684873
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Development of anti-adhesin mAbs and high-affinity ligand mimetics to treat and prevent UTIs
开发抗粘附素单克隆抗体和高亲和力配体模拟物来治疗和预防尿路感染
  • 批准号:
    10162827
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Development of anti-adhesin mAbs and high-affinity ligand mimetics to treat and prevent UTIs
开发抗粘附素单克隆抗体和高亲和力配体模拟物来治疗和预防尿路感染
  • 批准号:
    10577806
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Development of anti-adhesin mAbs and high-affinity ligand mimetics to treat and prevent UTIs
开发抗粘附素单克隆抗体和高亲和力配体模拟物来治疗和预防尿路感染
  • 批准号:
    10352469
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Characterizing the Contribution of the Group B Streptococcal Surface Adhesin BspC Interaction with Host Vimentin to Disease and Colonization
表征 B 族链球菌表面粘附素 BspC 与宿主波形蛋白相互作用对疾病和定植的贡献
  • 批准号:
    10312484
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了